Does PALBOCICLIB Cause Tumour marker increased? 817 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 817 reports of Tumour marker increased have been filed in association with PALBOCICLIB (Ibrance). This represents 0.9% of all adverse event reports for PALBOCICLIB.
817
Reports of Tumour marker increased with PALBOCICLIB
0.9%
of all PALBOCICLIB reports
23
Deaths
86
Hospitalizations
How Dangerous Is Tumour marker increased From PALBOCICLIB?
Of the 817 reports, 23 (2.8%) resulted in death, 86 (10.5%) required hospitalization, and 9 (1.1%) were considered life-threatening.
Is Tumour marker increased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PALBOCICLIB. However, 817 reports have been filed with the FAERS database.
What Other Side Effects Does PALBOCICLIB Cause?
Fatigue (15,190)
White blood cell count decreased (11,273)
Neoplasm progression (10,885)
Death (8,410)
Nausea (8,189)
Neutropenia (6,423)
Alopecia (6,201)
Diarrhoea (5,635)
Asthenia (3,660)
Off label use (3,405)
What Other Drugs Cause Tumour marker increased?
FULVESTRANT (408)
NIRAPARIB (356)
LETROZOLE (343)
RIBOCICLIB (317)
RUCAPARIB CAMSYLATE (257)
CAPECITABINE (228)
EVEROLIMUS (228)
ELACESTRANT (222)
OLAPARIB (171)
ANASTROZOLE (142)
Which PALBOCICLIB Alternatives Have Lower Tumour marker increased Risk?
PALBOCICLIB vs PALIPERIDONE
PALBOCICLIB vs PALIVIZUMAB
PALBOCICLIB vs PALONOSETRON
PALBOCICLIB vs PAMIDRONATE
PALBOCICLIB vs PAMIDRONIC ACID